Drs. Paul Karpecki, Derek Cunningham, Ben Gaddie, Cecelia Koetting, Jack Schaeffer, and Gina Wesley discuss the impact of presbyopia progression on a patient’s quality of life.
This activity is supported by an unrestricted educational grant from Orasis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
This podcast has no credit associated with it.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Paul M. Karpecki, OD, FAAO
Director of Cornea and External Disease
Kentucky Eye Institute
Lexington, Kentucky
Associate Professor
College of Optometry
University of Pikeville
Pikeville, Kentucky
Jack L. Schaeffer, OD, FAAO
Past President and Founder
Chief of Optometry
Schaeffer Eye Center
Birmingham, AL
Derek N. Cunningham, OD, FAAO
Co-Founder and President
Sports Vision Pros LLC
Director of Optometry and Clinical Research
Dell Laser Consultants
Austin, TX
Gina M. Wesley, OD, MD, FAAO
Optometrist
Complete Eye Care of Medina
Medina, Minnesota
Ian Benjamin Gaddie, OD, FAAO
Owner and Director
Gaddie Eye Centers
Louisville, Kentucky
Cecelia Koetting, OD, FAAO
Optometrist
Virginia Eye Consultants
Norfolk, Virginia
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Paul M. Karpecki, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan/AbbVie, Eyenovia, Ocuphire, and Orasis. Stock/Shareholder: Ocuphire and Orasis.
Jack L. Schaeffer, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Mati Therapeutics, Orasis, and Visus. Speaker’s Bureau: Alcon Vision, Allergan, Bausch + Lomb, Mati Therapeutics, Novartis, and Precipt. Stock/Shareholder: Mati Therapeutics, Orasis, Precipt, and Tearfilm.
Derek N. Cunningham, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Bausch + Lomb, Blephex, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, Orasis, and Sight Sciences.
Gina M. Wesley, OD, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bausch + Lomb and Orasis. Grant/Research Support: Alcon Vision, Coopervision, and Johnson & Johnson Vision. Stock/Shareholder: Bausch + Lomb.
Ian Benjamin Gaddie, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan and Orasis. Speaker’s Bureau: Aerie Pharmaceuticals, Allergan, and Bausch + Lomb. Stock/Shareholder: Orasis.
Cecelia Koetting, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Glaukos, Orasis, and Oyster Point. Speaker’s Bureau: RVL.
The Evolve and The Fundingsland Group planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group or Orasis Pharmaceuticals.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Eric D. Donnenfeld, MD
Marjan Farid, MD
Jason J. Jones, MD
Eva I. Liang, MD, FACS
Carlton Yuen, MD
